Page 2 - Kymab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kymab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kymab Today - Breaking & Trending Today

Insider Buying: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Director Purchases 62,516 Shares of Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) Director Johan Wedell-Wedellsborg purchased 62,516 shares of the stock in a transaction that occurred on Monday, November 27th. The shares were purchased at an average price of $5.49 per share, with a total value of $343,212.84. Following the completion of the acquisition, the director now directly owns […] ....

United States , Johan Wedell Wedellsborg , Rice Hall James Associates , Morgan Stanley , Victory Capital Management Inc , Avestar Capital , Acadian Asset Management , Y Mabs Therapeutics Inc , Jpmorgan Chase Co , Connor Clark Lunn Investment Management Ltd , Y Mabs Therapeutics , Get Free Report , Director Johan Wedell Wedellsborg , Abs Therapeutics , Asset Management , Lunn Investment Management , Hall James , Victory Capital Management , Y Mabs Therapeutics Daily , Nasdaq Ymab , Insider Trading , Nsider Trades ,

Y-mAbs Therapeutics (NASDAQ:YMAB) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note released on Wednesday, Benzinga reports. The brokerage currently has a $11.00 price target on the stock. HC Wainwright also issued estimates for Y-mAbs Therapeutics’ FY2023 earnings at ($0.65) EPS, Q1 2024 earnings at ($0.19) EPS, Q2 […] ....

United States , Acadian Asset Management , Avestar Capital , Morgan Stanley , Y Mabs Therapeutics Inc , Connor Clark Lunn Investment Management Ltd , Rice Hall James Associates , Jpmorgan Chase Co , Canaccord Genuity Group , Y Mabs Therapeutics , Free Report , Y Mabs Therapeutic , Genuity Group , Abs Therapeutics , Asset Management , Lunn Investment Management , Hall James , Get Free Report , Y Mabs Therapeutics Daily , Nasdaq Ymab , Reiterated Rating , Hc Wainwright ,

Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $11.86

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have earned an average rating of “Hold” from the ten analysts that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the […] ....

United States , Zurcher Kantonalbank Zurich Cantonalbank , Y Mabs Therapeutics Company Profile , Morgan Stanley , Canaccord Genuity Group , Y Mabs Therapeutics Inc , Tower Research Capital , Avestar Capital , Jpmorgan Chase Co , Y Mabs Therapeutics , Get Free Report , Marketbeat Ratings , Abs Therapeutics , Research Capital , Kantonalbank Zurich Cantonalbank , Get Free , Y Mabs Therapeutics Daily , Nasdaq Ymab ,

Avestar Capital LLC Takes Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Avestar Capital LLC acquired a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $68,000. A number of other hedge funds have […] ....

United States , Jpmorgan Chase Co , Denali Advisors , Morgan Stanley , Victory Capital Management Inc , Canaccord Genuity Group , Avestar Capital , Exchange Commission , Rice Hall James Associates , Exchange Traded Concepts , Y Mabs Therapeutics Company Profile , Y Mabs Therapeutics Inc , Y Mabs Therapeutics , Free Report , Capital Management , Hall James , Traded Concepts , Abs Therapeutics , Get Free Report , Genuity Group , Y Mabs Therapeutics Daily , Nasdaq Ymab , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $12.63 Average PT from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been assigned a consensus rating of “Hold” from the eleven research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and four have assigned a buy recommendation to the […] ....

United States , Y Mabs Therapeutics Inc , Pricet Rowe Associates Inc , Morgan Stanley , Rice Hall James Associates , Jpmorgan Chase Co , Canaccord Genuity Group , Y Mabs Therapeutics Company Profile , Principal Financial Group Inc , Algert Global , Y Mabs Therapeutics , Get Free Report , Genuity Group , Hall James , Financial Group , Abs Therapeutics , Get Free , Y Mabs Therapeutics Daily , Nasdaq Ymab ,